Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Sep;20(3):351–355. doi: 10.1128/aac.20.3.351

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

R Platt, S L Ehrlich, J Afarian, T F O'Brien, J E Pennington, E H Kass
PMCID: PMC181699  PMID: 6458233

Abstract

Thirty patients infected predominantly by Serratia marcescens and Pseudomonas aeruginosa were treated in an open trial with moxalactam, a broad-spectrum beta-lactam antibiotic. Twenty-three (76%) had a satisfactory microbiological or clinical response. Among 25 patients for whom serum inhibitory concentrations were measured, those with favorable microbiological responses had significantly higher values than those with poor responses (reciprocal geometric mean concentrations, 49 versus 4.9; P less than 0.01). A serum inhibitory concentration of greater than 1:8 correlated significantly with a favorable outcome (17 of 18 versus 2 of 7 responses; P less than 0.01). Although the overall clinical efficacy of moxalactam was good, resistant organisms of species identical to those of the original infecting isolates were recovered during therapy in seven cases, including five caused by Pseudomonas organisms and two caused by Serratia organisms.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Darrell J. H., Waterworth P. M. Carbenicillin resistance in Pseudomonas aeruginosa from clinical material. Br Med J. 1969 Jul 19;3(5663):141–143. doi: 10.1136/bmj.3.5663.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fisher L. S., Chow A. W., Yoshikawa T. T., Guze L. B. Cephalothin and cephaloridine therapy for bacterial meningitis. Ann Intern Med. 1975 May;82(5):689–693. doi: 10.7326/0003-4819-82-5-689. [DOI] [PubMed] [Google Scholar]
  4. Graybill J. R., Marshall L. W., Charache P., Wallace C. K., Melvin V. B. Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis. 1973 Nov;108(5):1130–1140. doi: 10.1164/arrd.1973.108.5.1130. [DOI] [PubMed] [Google Scholar]
  5. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  6. Mangi R. J., Quintiliani R., Andriole V. T. Gram-negative bacillary meningitis. Am J Med. 1975 Dec;59(6):829–836. doi: 10.1016/0002-9343(75)90468-4. [DOI] [PubMed] [Google Scholar]
  7. Sande M. A., Johnson W. D., Jr, Hook E. W., Kaye D. Sustained bacteremia in patients with prosthetic cardiac valves. N Engl J Med. 1972 May 18;286(20):1067–1070. doi: 10.1056/NEJM197205182862001. [DOI] [PubMed] [Google Scholar]
  8. Winters R. E., Litwack K. D., Hewitt W. L. Relation between dose and levels of gentamicin in blood. J Infect Dis. 1971 Dec;124 (Suppl):S90–S95. doi: 10.1093/infdis/124.supplement_1.s90. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES